Ethylbutyrate, a valproate-like compound, exhibits inositol-depleting effects - A potential mood-stabilizing drug

Life Sciences

Volumn 84, Issue 1-2, 2009, Pages 38-44

  Azab, Abed N ^a   Mehta, Dhara V ^a   Chesebro, John E ^a   Greenberg, Miriam L ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Bipolar disorder; Inositol; Valproate; Yeast

Indexed keywords

1 MYO INOSITOL 3 PHOSPHATE SYNTHASE; 2 ETHYL BUTYRIC ACID; BUTYRIC ACID; BUTYRIC ACID ETHYL ESTER; FUNGAL RNA; HEXANOIC ACID; INOSITOL; MOOD STABILIZER; PROPYL HEXANOATE; UNCLASSIFIED DRUG; VALPROIC ACID;

ARTICLE; BIOSYNTHESIS; CELL GROWTH; CHEMICAL STRUCTURE; CHROMATOGRAPHY; CONTROLLED STUDY; ENZYME ACTIVITY; FLUOROMETRY; NONHUMAN; NORTHERN BLOTTING; OPTICAL DENSITY; SACCHAROMYCES CEREVISIAE; SPECTROPHOTOMETRY;

AFFECT; BIPOLAR DISORDER; BUTYRATES; CELL PROLIFERATION; HUMANS; INOSITOL; INTRAMOLECULAR LYASES; SACCHAROMYCES CEREVISIAE; VALPROIC ACID;

SACCHAROMYCES CEREVISIAE;

EID: 57649233178     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2008.10.016     Document Type: Article

References (63)

1. Atack J.R. Lithium, phosphatidylinositol signaling, and bipolar disorder. The role of inositol monophosphatase. In: Manji H.K., Bowden C.L., and Belmaker R.H. (Eds). Bipolar Medications: Mechanism of Action (2000), American Psychiatric Publishing, Washington, DC 1-30
2. Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A., Strul, K., 1994. Current Protocols in Molecular Biology. 13.12. Wiley Interscience, John Wiley and Sons Inc., New York.
3. Azab A.N., Agam G., Kaplanski J., Delbar V., and Greenberg M.L. Inositol depletion: a good or bad outcome of valproate treatment. Future Neurology 3 (2008) 275-286
4. Azab A.N., He Q., Ju S., Li G., and Greenberg M.L. Glycogen synthase kinase-3 is required for optimal de novo synthesis of inositol. Molecular Microbiology 63 (2007) 1248-1258
5. Belmaker R.H. Bipolar disorder. New England Journal of Medicine 351 (2004) 476-486
6. Berridge M.J., Downes C.P., and Hanley M.R. Lithium amplifies agonist-dependent phophatidyl-inositol responses in brain and salivary glands. Biochemical Journal 206 (1982) 587-595
7. Berridge M.J., and Irvine R.F. Inositol phosphates and cell signaling. Nature 341 (1989) 197-204
8. Bostwick J.M., and Pankratz V.S. Affective disorders and suicide risk: a reexamination. American Journal of Psychiatry 157 (2000) 1925-1932
9. Bowden C.L., Brugger A.M., Swann A.C., Calabrese J.R., Janicak P.G., Petty F., Dilsaver S.C., Davis J.M., Rush A.J., and Small J.G. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 271 (1994) 918-924
10. Bowden C.L. Making optimal use of combination pharmacotherapy in bipolar disorder. Journal of Clinical Psychiatry 65 (2004) 21-24
11. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Annals of Biochemistry 72 (1976) 248-254
12. Brodensen A., Licht R.W., Vestergaard P., Olensen A.V., and Mortensen P.B. Sixteen-year mortality in patients with affective disorder commenced on lithium. British Journal of Psychiatry 176 (2000) 429-433
13. Buggy J.J., Sideris M.L., Lorimer D.D., McIntoch B., and Clark J.M. Cloning and characterization of a novel histone deacetylase, HDAC8. Biochemical Journal 1 (2000) 199-205
14. Carman G.M., and Henry S.A. Phospholipid biosynthesis in the yeast Saccharomyces cerevisiae and interrelationship with other metabolic processes. Progress in Lipid Research 38 (1999) 361-399
15. Casebolt T.L., and Jope R.S. Long-term lithium treatment selectively reduces receptor-coupled inositol phospholipid hydrolysis in rat brain. Biological Psychiatry 25 (1989) 329-340
16. Chapman A.G., Groucher M.J., and Meldrum B.S. Anticonvulsant activity of intracerebroventricularly administered valproate and valproate analogues. A dose-dependent correlation with changes in brain aspartate and GABA levels in DBA/2 mice. Biochemistry and Pharmacology 33 (1984) 1459-1463
17. Chen I.W., and Charalampous C.F. Biochemical studies on inositol. IX. d-Inositol 1-phosphate as intermediate in the biosynthesis of inositol from glucose 6-phosphate, and characteristics of two reactions in this biosynthesis. Journal of Biological Chemistry 241 (1966) 2194-2199
18. Colletti R.B., Trainer T.D., and Krawisz B.R. Reversible valproate fulminant hepatic failure. Journal of Pediatric Gastroenterology and Nutrition 5 (1986) 990-994
19. Culbertson M.R., Donahue T.F., and Henry S.A. Control of inositol biosynthesis in Saccharomyces cerevisiae: properties of a repressible enzyme system in extracts of wild-type (Ino+) cells. Journal of Bacteriology 126 (1976) 232-242
20. Davanzo P., Thomas M.A., Yue K., Oshiro T., Belin T., Strober M., and McCracken J. Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. Neuropsychopharmacology 24 (2001) 359-369
21. De Sarno P., Li X., and Jope R.S. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43 (2002) 1158-1164
22. Einat H., Tian F., Belmaker R.H., and Frost J.W. Myo-inositol-1-phosphate (MIP) synthase inhibition: in-vivo study in rats. Journal of Neural transmission 115 (2008) 55-58
23. Ghaemi S.N., Gilmer W.S., Goldberg J.F., Zablotsky B., Kemp D.E., Kelley M.E., Beuer A.D., Fleck J., Filkowski M.M., Stan V.A., and Dunn R.T. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. Journal of Clinical Psychiatry 68 (2007) 1840-1844
24. Gitlin M. Treatment-resistant bipolar disorder. Molecular Psychiatry 11 (2006) 227-240
25. Godfrey P.P., McClue S.J., White A.M., Wood A.J., and Grahame-Smith D.G. Subacute and chronic in vivo lithium treatment inhibits agonist- and sodium fluoride-stimulated inositol phosphate production in rat cortex. Journal of Neurochemistry 52 (1989) 498-506
26. Greenberg M.L., and Lopes J.M. Genetic regulation of phospholipid biosynthesis in yeast. Microbiology Reviews, 60 (1996) 1-20
27. Grimes C.A., and Jope R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Progress in Neurobiology 65 (2001) 391-426
28. Hirsch J.P., and Henry S.A. Expression of the Saccharomyces cerevisiae inositol-1-phosphate synthase (INO1) gene is regulated by factors that affect phospholipid synthesis. Molecular and Cellular Biology 6 (1986) 3320-3328
29. Jope R.S., and Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends in Biological Sciences 29 (2004) 95-102
30. Ju S., and Greenberg M.L. Valproate disrupts regulation of inositol responsive genes and alters regulation of phospholipid biosynthesis. Molecular Microbiology 49 (2003) 1595-1603
31. Ju S., Shaltiel G., Shamir A., Agam G., and Greenberg M.L. Human 1-d-myo-inositol-3-phosphate synthase is functional in yeast. Journal of Biological Chemistry 279 (2004) 21759-21765
32. Judd J.L., Akiskal H.S., Schettler P.J., Coryell W., Endicott J., Maser J.D., Solomon D.A., Leon A.C., and Keller M.B. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Archives of General Psychiatry 60 (2003) 261-269
33. Judd J.L., Akiskal H.S., Schettler P.J., Endicott J., Maser J., Solomon D.A., Leon A.C., Rice J.A., and Keller M.B. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry 59 (2002) 530-537
34. Kendall D.A., and Nahorski S.R. Acute and chronic lithium treatments influence agonist and depolarization-stimulated inositol phospholipid hydrolysis in rat cerebral cortex. Journal of Pharmacological and Experimental Therapeutics 241 (1987) 1023-1027
35. Klein P.S., and Melton D.A. A molecular mechanism for the effect of lithium on development. Proceedings of the National Academy of Sciences USA 93 (1996) 8455-8459
36. Lea M.A., and Tulsyan N. Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase. Anticancer research 15 (1995) 879-883
37. Loescher W. Valproic acid mechanisms of action. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic Drugs (2002), Lippincott Williams & Wilkins, Philadelphia 767-779
38. Loewus M.W., Loewus F.A., Brillinger G.U., Otsuka H., and Floss H.G. Stereochemistry of the myo-inositol-1-phosphate synthase reaction. Journal of Biological Chemistry 255 (1980) 11710-11712
39. Maslanski J.A., and Busa W.B. A sensitive and specific mass assay for myo-inositol and inositol phosphates. In: Irvine R.F. (Ed). Methods in Inositide Research (1990), Raven Press Ltd., New York 113-126
40. Minskoff S.A., Racenis P.V., Granger J., Larkins L., Hajra A.K., and Greenberg M.L. Regulation of phosphatidic acid biosynthetic enzymes in Saccharomyces cerevisiae. Journal of Lipid Research 35 (1994) 2254-2262
41. Moore G.J., Bebchuk J.M., Parrish J.K., Faulk M.W., Arfken C.L., Strahl-Bevaqua J., and Manji H.K. Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. American Journal of Psychiatry 156 (1999) 1902-1908
42. Narrow W.E., Rae D.S., and Robins L.N. Revised prevalence estimates of mental disorders in the United States: using clinical significance criterion to reconcile 2 surveys' estimates. Archives of General Psychiatry 59 (2002) 115-123
43. Nikawa J., Tsukagoshi Y., and Yamashita S. Isolation and characterization of two distinct myo-inositol transporter genes of Saccharomyces cerevisiae. Journal of Biological Chemistry 266 (1991) 11184-11191
44. O'Donnel T., Rotzinger S., Nakashima T.T., Hanstock C.C., Ulrich M., and Silverstone P.H. Chronic lithium and sodium valproate both decrease the concentration of myo-inositol and increase the concentration of inositol monophosphatases in rat brain. Brain Research 880 (2000) 84-91
45. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16 (2002) 695-714
46. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., and Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. Journal of Biological Chemistry 276 (2001) 36734-36741
47. Pollack S.J., Atack J.R., Knowles M.R., McAllister G., Ragan C.I., Baker R., Fletcher S.R., Iversen L.L., and Broughton H.B. Mechanism of inositol monophosphatase, the putative target of lithium therapy. Proceedings of the National Academy of Sciences USA 91 (1994) 5766-5770
48. Robert E., and Rosa F. Valproate and birth defects. Lancet 2 (1983) 1142
49. Robinson K.S., Lai K., Cannon T.A., and McGraw P. Inositol transport in Saccharomyces cerevisiae is regulated by transcriptional and degradative endocytic mechanisms during the growth cycle that are distinct from inositol-induced regulation. Molecular Biology of the Cell 7 (1996) 81-89
50. Schroeder F.A., Lin C.L., Crusio W.E., and Akbarian S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biological Psychiatry 62 (2007) 55-64
51. Shaldubina A., Buccafusca R., Johanson R.A., Agam G., Belmaker R.H., Berry G.T., and Bersudsky Y. Behavioral phenotyping of sodium-myo-inositol cotransporter heterozygous knockout mice with reduced brain inositol. Genes Brain and Behavior 6 (2007) 253-259
52. Shaldubina A., Stahl Z., Furszpan M., Regenold W.T., Belmaker R.H., and Bersudsky Y. Inositol deficiency diet and lithium effects. Bipolar Disorders 8 (2006) 152-159
53. Shaldubina A., Johanson R.A., O'Brien W.T., Buccafusca R., Agam G., Belmaker R.H., Bersudsky Y., and Berry G.T. SMIT1 haploinsufficiency causes brain inositol deficiency without affecting lithium-sensitive behavior. Molecular Genetics and Metabolism 88 (2006) 384-388
54. Shaltiel G., Shamir A., Shapiro J., Ding D., Dalton E., Bialer M., Harwood A.J., Belmaker R.H., Greenberg M.L., and Agam G. Valproate decreases inositol biosynthesis. Biological Psychiatry 56 (2004) 868-874
55. Shears S.B. Metabolism of the inositol phosphates produced upon receptor activation. Biochemical Journal 260 (1989) 313-324
56. Silverstone P.H., Wu R.H., O'Donnell T., Ulrich M., Asghar S.J., and Handstock C.C. Chronic treatment with both lithium and sodium valproate may normalize phosphoinositol cycle activity in bipolar patients. Human Psychopharmacology 17 (2002) 321-327
57. Soreca I., Fagiolini A., Frank E., Houck P.R., Thompson W.K., and Kupfer D.J. Relationship of general medical burden, duration of illness and age in patients with bipolar I disorder. Journal of Psychiatric Research. 42 (2008) 956-961
58. Stambolic V., Ruel L., and Woodgett J.R. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Current Biology 6 (1996) 1664-1668
59. Tohen M., Greil W., Calabrese J.R., Sachs G.S., Yatham L.N., Oerlinghaunsen B.M., Koukopoulos A., Cassano G.B., Grunze H., Licht R.W., Dell'Osso L., Evans A.R., Risser R., Baker R.W., Crane H., Dossenbach M.R., and Bowden C.L. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. American Journal of Psychiatry 162 (2005) 1281-1290
60. Vaden D.L., Ding D., Peterson B., and Greenberg M.L. Lithium and valproate decrease inositol mass and increase expression of the yeast INO1 and INO2 genes for inositol biosynthesis. Journal of Biological Chemistry 276 (2001) 15466-15471
61. Verotti A., Tana M., Pelliccia P., Chiarelli F., and Latini G. Recent advances on neural tube defects with special reference to valproic acid. Endocrine Metabolic and Immune Disorders Drug Targets 6 (2006) 25-31
62. Werstuck G.H., Kim A.J., Brenstrum T., Ohnmacht S.A., Panna E., and Capretta A. Examining the correlations between GSK-3 inhibitory properties and anti-convulsant efficacy of valproate and valproate-related compounds. Bioorganic and Medicinal Chemistry Letters 14 (2004) 5465-5467
63. Williams R.S.B., Cheng L., Mudge A.W., and Harwood A.J. A common mechanism of action for three mood-stabilizing drugs. Nature 417 (2002) 292-295